Literature DB >> 25749786

Multivariate modelling of prostate cancer combining magnetic resonance derived T2, diffusion, dynamic contrast-enhanced and spectroscopic parameters.

S F Riches1, G S Payne, V A Morgan, D Dearnaley, S Morgan, M Partridge, N Livni, C Ogden, N M deSouza.   

Abstract

OBJECTIVES: The objectives are determine the optimal combination of MR parameters for discriminating tumour within the prostate using linear discriminant analysis (LDA) and to compare model accuracy with that of an experienced radiologist.
METHODS: Multiparameter MRIs in 24 patients before prostatectomy were acquired. Tumour outlines from whole-mount histology, T2-defined peripheral zone (PZ), and central gland (CG) were superimposed onto slice-matched parametric maps. T2, Apparent Diffusion Coefficient, initial area under the gadolinium curve, vascular parameters (K(trans),Kep,Ve), and (choline+polyamines+creatine)/citrate were compared between tumour and non-tumour tissues. Receiver operating characteristic (ROC) curves determined sensitivity and specificity at spectroscopic voxel resolution and per lesion, and LDA determined the optimal multiparametric model for identifying tumours. Accuracy was compared with an expert observer.
RESULTS: Tumours were significantly different from PZ and CG for all parameters (all p < 0.001). Area under the ROC curve for discriminating tumour from non-tumour was significantly greater (p < 0.001) for the multiparametric model than for individual parameters; at 90 % specificity, sensitivity was 41 % (MRSI voxel resolution) and 59 % per lesion. At this specificity, an expert observer achieved 28 % and 49 % sensitivity, respectively.
CONCLUSION: The model was more accurate when parameters from all techniques were included and performed better than an expert observer evaluating these data. KEY POINTS: • The combined model increases diagnostic accuracy in prostate cancer compared with individual parameters • The optimal combined model includes parameters from diffusion, spectroscopy, perfusion, and anatominal MRI • The computed model improves tumour detection compared to an expert viewing parametric maps.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25749786     DOI: 10.1007/s00330-014-3479-0

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  39 in total

1.  Automatic quantitation of localized in vivo 1H spectra with LCModel.

Authors:  S W Provencher
Journal:  NMR Biomed       Date:  2001-06       Impact factor: 4.044

2.  Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study.

Authors:  Tom W J Scheenen; Jurgen Fütterer; Elisabeth Weiland; Paul van Hecke; Marc Lemort; Christian Zechmann; Heinz-Peter Schlemmer; Dale Broome; Geert Villeirs; Jianping Lu; Jelle Barentsz; Stefan Roell; Arend Heerschap
Journal:  Invest Radiol       Date:  2011-01       Impact factor: 6.016

3.  Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection.

Authors:  Stefan A Reinsberg; Geoffrey S Payne; Sophie F Riches; Sue Ashley; Jonathan M Brewster; Veronica A Morgan; Nandita M deSouza
Journal:  AJR Am J Roentgenol       Date:  2007-01       Impact factor: 3.959

4.  Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis.

Authors:  Aytekin Oto; Cheng Yang; Arda Kayhan; Maria Tretiakova; Tatjana Antic; Christine Schmid-Tannwald; Scott Eggener; Gregory S Karczmar; Walter M Stadler
Journal:  AJR Am J Roentgenol       Date:  2011-12       Impact factor: 3.959

5.  Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology.

Authors:  A E Wefer; H Hricak; D B Vigneron; F V Coakley; Y Lu; J Wefer; U Mueller-Lisse; P R Carroll; J Kurhanewicz
Journal:  J Urol       Date:  2000-08       Impact factor: 7.450

6.  MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters.

Authors:  Sophie F Riches; Geoffrey S Payne; Veronica A Morgan; Samir Sandhu; Cyril Fisher; Michael Germuska; David J Collins; Alan Thompson; Nandita M deSouza
Journal:  AJR Am J Roentgenol       Date:  2009-12       Impact factor: 3.959

7.  Can high-spatial resolution T2-weighted endorectal MRI rule out clinically significant prostate cancer?

Authors:  Matthias C Roethke; Michaela Kniess; Sascha Kaufmann; Matthias P Lichy; Heinz-Peter Schlemmer; Arnulf Stenzl; David Schilling
Journal:  World J Urol       Date:  2013-06-11       Impact factor: 4.226

8.  Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study.

Authors:  Jeffrey C Weinreb; Jeffrey D Blume; Fergus V Coakley; Thomas M Wheeler; Jean B Cormack; Christopher K Sotto; Haesun Cho; Akira Kawashima; Clare M Tempany-Afdhal; Katarzyna J Macura; Mark Rosen; Scott R Gerst; John Kurhanewicz
Journal:  Radiology       Date:  2009-04       Impact factor: 11.105

9.  Dynamic contrast-enhanced MRI for prostate cancer localization.

Authors:  A S N Jackson; S A Reinsberg; S A Sohaib; E M Charles-Edwards; S Jhavar; T J Christmas; A C Thompson; M J Bailey; C M Corbishley; C Fisher; M O Leach; D P Dearnaley
Journal:  Br J Radiol       Date:  2009-02       Impact factor: 3.039

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more
  9 in total

1.  The evaluation of prostate lesions with IVIM DWI and MR perfusion parameters at 3T MRI.

Authors:  Murat Beyhan; Recep Sade; Erdem Koc; Senol Adanur; Mecit Kantarci
Journal:  Radiol Med       Date:  2018-10-01       Impact factor: 3.469

2.  Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha-tocolpherol, beta-carotene cancer prevention (ATBC) study.

Authors:  Alison M Mondul; Steven C Moore; Stephanie J Weinstein; Edward D Karoly; Joshua N Sampson; Demetrius Albanes
Journal:  Int J Cancer       Date:  2015-05-09       Impact factor: 7.396

3.  Diagnostic value and relative weight of sequence-specific magnetic resonance features in characterizing clinically significant prostate cancers.

Authors:  Olivier Rouvière; Tristan Dagonneau; Fanny Cros; Flavie Bratan; Laurent Roche; Florence Mège-Lechevallier; Alain Ruffion; Sébastien Crouzet; Marc Colombel; Muriel Rabilloud
Journal:  PLoS One       Date:  2017-06-09       Impact factor: 3.240

4.  A Novel Unsupervised Segmentation Approach Quantifies Tumor Tissue Populations Using Multiparametric MRI: First Results with Histological Validation.

Authors:  Prateek Katiyar; Mathew R Divine; Ursula Kohlhofer; Leticia Quintanilla-Martinez; Bernhard Schölkopf; Bernd J Pichler; Jonathan A Disselhorst
Journal:  Mol Imaging Biol       Date:  2017-06       Impact factor: 3.488

5.  The role of imaging in the diagnosis of primary prostate cancer.

Authors:  Hugh Harvey; Nandita M deSouza
Journal:  J Clin Urol       Date:  2016-12-01

6.  Volumetry of the dominant intraprostatic tumour lesion: intersequence and interobserver differences on multiparametric MRI.

Authors:  Hugh Harvey; Matthew R Orton; Veronica A Morgan; Chris Parker; David Dearnaley; Cyril Fisher; Nandita M deSouza
Journal:  Br J Radiol       Date:  2017-01-05       Impact factor: 3.039

7.  MRI Based Radiomics Compared With the PI-RADS V2.1 in the Prediction of Clinically Significant Prostate Cancer: Biparametric vs Multiparametric MRI.

Authors:  Tong Chen; Zhiyuan Zhang; Shuangxiu Tan; Yueyue Zhang; Chaogang Wei; Shan Wang; Wenlu Zhao; Xusheng Qian; Zhiyong Zhou; Junkang Shen; Yakang Dai; Jisu Hu
Journal:  Front Oncol       Date:  2022-01-20       Impact factor: 6.244

Review 8.  DCE-MRI, DW-MRI, and MRS in Cancer: Challenges and Advantages of Implementing Qualitative and Quantitative Multi-parametric Imaging in the Clinic.

Authors:  Jessica M Winfield; Geoffrey S Payne; Alex Weller; Nandita M deSouza
Journal:  Top Magn Reson Imaging       Date:  2016-10

Review 9.  Quantitative imaging of cancer in the postgenomic era: Radio(geno)mics, deep learning, and habitats.

Authors:  Sandy Napel; Wei Mu; Bruna V Jardim-Perassi; Hugo J W L Aerts; Robert J Gillies
Journal:  Cancer       Date:  2018-11-01       Impact factor: 6.860

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.